Chord Therapeutics: New oral treatments for NMOSD & myasthenia gravis
Founder Arthur Roach and CEO Tom Plitz introduce Chord Therapeutics’ mission to bring new oral treatments to patients with rare diseases. Chord Therapeutics launches with USD 16 million Series A investment from Omega Funds.